The endothelial nitric oxide synthase gene ( 
Introduction
Nitric oxide synthases (NOS) are enzymes which metabolize L-arginine to form nitric oxide (NO), and three isoforms have been identified. In the vascular system, the NOS III isoform (eNOS), first identified in endothelial cells, regulates vascular tone (1), platelet aggregation (2) and smooth muscle cell proliferation (3) . The enzyme is activated by increased intracellular calcium concentration and by translocation from caveolae to cytosol (for review see (4) ). The eNOS expression is constitutive in endothelial cells but under several physiological and pathological conditions, transcriptional regulation (5, 6) and changes in mRNA stability (7, 8) have been described. Several studies were aimed at characterizing the 5'-upstream sequences that drive transcriptional activity of the promoter up to 3500 bp. A major transcriptional effect was identified for Sp-1/Sp-3 and GATA-2 transcription factors, for which binding sites are located respectively at -103 and -230 bp upstream from the major transcription start site (9) (10) (11) . A second positive regulatory domain was detected between -140/-120 bp in the proximal promoter (12) . It was also shown that a 1600 bp human eNOS (heNOS) promoter fragment allows the endothelial expression of a reporter gene in transgenic mice, but is not sufficient to observe a full expression of the gene in all endothelial territories and to reproduce the endogenous pattern of expression (13) .
Sense (pGL3-p2) and anti-sense (pGL3-p42) constructs, containing the 269 bp activator element (-4907/-4638) in both orientations, were generated by sub-cloning a 269 bp pfu polymerase amplification product 5' to the 1703 bp promoter fragment of the heNOS gene. For pointmutation generation, a commercial kit (Quick Change mutagenesis kit, Stratagene) was used with pGL3-p2 as template. Constructs and mutants were checked by sequencing.
Transient Transfection Assays-Transfection assays were carried out using polyethyleneimine (PEI) suspension in a commercially available solution (EXGEN 500).
Briefly, HMEC-1 and HeLa cells were seeded on 2 cm 2 multidish plates at 100x10 3 /well and 50x10 3 /well respectively, incubated 24 hours, then treated with a buffer (150 mM NaCl) containing 0.134 pmoles of the relevant reporter gene vector, 0.134 pmoles of pRenilla luciferase gene vector (Promega) as transfection standardizing control and polyethyleneimine suspension (4 µl for 2 µg of total DNA). Co-expression experiments were performed using expression vectors containing cDNA for various transcription factors, pCDNA1-Ets-2 (gift of Dr. J.
Leiden), pCDNA1-Elf-1 (18), pSG5-Ets1 (19) , pCMV5-Elk-1-FLAG (gift of Dr. R. Davis); pSG5-p55-Erg (20) and pCDNA3-kz-MZF-1 (gift of Dr. J. Morris). Identical experimental procedures were used, except that relevant expression vectors were included in PEI suspension at convenient ratio compared to reporter vector. Luciferase activity was measured by luminometry using Dual luciferase revelation system (Promega) as described by the manufacturer.
Preparation of protein extracts-HMEC-1 nuclear extracts were prepared as previously described (21) . For whole cell extract preparation, HeLa cells were seeded on a 2 cm 2 multidish plate and transfected with 2 µg of relevant expression vectors or empty control vectors. After 40 hours, the cells were harvested in 40 mM Tris-HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, collected by low speed centrifugation (800 g, 4˚C), then resuspended in 40 µl of buffer containing 20 mM Tris-HCl pH 7.4, 0.4 M KCl, 2 mM Dithiothreitol (DTT), 10% glycerol.
Cells were broken by freezing and thawing (3X), cell debris were removed by centrifugation (800 g, 10 min., 4˚C), and the supernatant (whole cell extract) was aliquoted and stored at -70 ˚C.
DNase I Footprinting Analysis-A fragment of the heNOS gene promoter region (-4907 to -4638) was obtained by PCR amplification using primers flanking the enhancer. For radioactive labelling, one primer (1.5 pmoles) was end-labeled with γ[ 32 P]ATP by T 4 DNA polynucleotide kinase (Life Technologies) before a 20 cycle-PCR amplification using 10 pmoles of the second primer. DNase I footprinting analyses were performed by incubating 5,000 cpm of probe with 20 to 30 µg of nuclear extracts for 15 minutes, at room temperature, in 25 mM Hepes, 50 mM KCl, 0.1 mM EDTA, 5 mM MgCl 2 , 5 mM CaCl 2 , 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM DTT, 10% Glycerol before submission to increasing amounts of DNase I for 2 minutes. Control reactions were performed in the absence of proteins. Reactions were stopped by addition of stop buffer (200 µg proteinase K, EDTA 50 mM, tRNA 100 µg/ml, 1% SDS) and incubated 1 hour at 50˚C. Samples were phenol extracted, ethanol precipitated and recovered in (98% formamide, 10 mM EDTA, 0.1% BPB, 0.1% xylene cyanol), denatured and loaded, together with a G+A Maxam-Gilbert sequence of the probe, on a 6% acrylamide-8 M Urea sequencing gel.
Linker-scanning Mutants Generation-Seven linker-scanning mutations were introduced in the pGL3-p2 construct. For each mutant, 2 amplicons, the 5' and the 3', were synthesized using a PCR-based method with pfu polymerase. Primers used to create the linker-scanning mutants are listed in Table I . The 5' amplicon was generated using two primers designated MluB10 and Brx. MluB10 is a gene specific, sense primer which corresponds to the -4907/-4883 region of the heNOS promoter and has a Mlu I restriction site at its 5' end. Brx primers, where x corresponds to the location of the specific bases to be mutated, are 24 to 29 base antisense primers containing a sequence identical to the promoter sequence linked to a mutated region at the 5'-end, heterologous to the heNOS sequence and containing a restriction site. The 3' amplicon was generated similarly using a common anti-sense primer HSFP3' (positions -4684/-4638) and different Scx primers containing a sequence identical to heNOS promoter and a 5'-end heterologous to the heNOS sequence and containing a restriction site identical to the corresponding Brx oligonucleotide. After restriction digestion and purification, each 5' amplicon was ligated to its corresponding 3' amplicon and the ligation product was submitted to a further pfu amplification reaction. The 269-bp mutated product was then subcloned in front of the 1703 bp promoter in pGL3-1703 construct. Clones obtained were checked by sequencing.
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Electrophoretic Mobility Shift Assay-Oligonucleotides corresponding to DNase I protected regions were designed according to the sequence established previously (see Table II ).
Crude nuclear extracts (5-7 µg) or whole cell extracts of cells transfected with expression vector (Fig. 1A) , 3 hypersensitive sites were detected by Southern blot experiments in the heNOS gene in HMEC-1 (Fig. 1B) . From the size of these fragments, it can be deduced that these sites are located approximately at 5 kb (HS1), 1.9 kb (HS2), and 0.9 kb (HS3) upstream from the major transcription start site (Fig. 1A ). The distal hypersensitive site (HS1) does not correspond to any previously identified regulatory regions of the heNOS promoter. Using HeLa cells which do not express eNOS, as observed by RT-PCR (data not shown), none of these hypersensitive sites could be detected in similar experiments (Fig. 1C) . (Fig. 2D) . A large increase of transcriptional activity was also observed when using the pGL3-SV40-Enh construct compared to pGL3-SV40 in HeLa (Fig. 2D) .
Results

Identification of endothelial specific
In vitro analysis of the enhancer region of heNOS promoter-
DNase I footprint experiments were performed to identify regulatory elements involved in the heNOS distal enhancer activity. An end-labeled PCR-product corresponding to the 269 bp activator element of the promoter was used as a probe in footprint experiments with HMEC-1 nuclear extracts. As shown in figure 3 , nuclear proteins protected the sense probe in four regions, named A, B, C, and D (Fig. 3A) . The protected element A spans 8 bp and is limited in Using an anti-sense probe, we observed protection over elements A, B, and C, but element D was not protected (Fig. 3A) . To understand the role of each DNase I protected element, a systematic mutational analysis was conducted by mutating 8 to 10 bp of each element (see Table I ). These linker-scanning studies allowed functional binding sites to be identified among the four DNase I protected elements. Five linker-scanning mutants (pGL3-p2-LSA, pGL3-p2-LSB2, pGL3-p2-LSC2, pGL3-p2-LSC3, pGL3-p2-LSD) showed a clear, significant decrease in transcriptional activity compared to the pGL3-p2 wild-type construct in HMEC-1 (Fig. 4) . The mutants pGL3-p2-LSA, pGL3-p2-LSC2 and pGL3-p2-LSD conserved 30-35% of the enhancer activity, while pGL3-p2-LSB2 and pGL3-p2-LSC3 no longer exhibited an enhancer effect. In contrast, the linker-scanning mutant pGL3-p2-LSB1 kept 60% of the enhancer activity and the linkerscanning mutant pGL3-p2-LSC1 had no effect on enhancer activity. These data demonstrate the functional role of five regions of the enhancer in the regulation of basal heNOS expression.
Nucleoprotein complexes formed by element A-
A 34 bp oligonucleotide (FPA-WT) was designed to be centered on footprint element A, overlapping 15 bp of footprint B (Fig. 5A ). Several DNA-protein complexes were observed when using a labeled FPA-WT probe in EMSA experiments (Fig. 5C, lanes 2, 12) . Addition of 10-to 100-fold molar excess of cold competitor FPA-WT oligonucleotide, suppressed all the complexes (lanes 3-4, [13] [14] . Computer analysis of the FPA-WT sequence revealed putative binding sites for several transcription factors located in element A, in particular for MZF-1 zincfinger transcription factors and for Krüppel-like transcription factors family members (Fig. 5A ).
FPA derived oligonucleotides were designed ( Fig. 5B and Table II Despite the fact that HMEC-1 cells seem to express MZF-1 (as seen with RT-PCR and western blot analysis, data not shown) and MZF-1b (western blot analysis, data not shown), we were unable to observe any supershift using either the MZF-1/1b antibody, or an antibody specifically targeted against the N-terminal domain of MZF-1b (data not shown). Similarly, coexpression of MZF-1 expression vector with pGL3-p2 plasmid had no effect on the enhancer transcriptional activation (data not shown). 
Nucleoprotein complexes formed by element C-
Nucleoprotein complexes formed by element B and D
Incubation of the labeled FPB2-WT probe, centered on the region B2 ( Fig. 7A ) with HMEC-1 nuclear extracts resulted in a DNA-protein complex formation (Fig. 7B, lane 2) , which was completely prevented with cold FPB2-WT competitor (Fig. 7B, lane 3) . Computer analysis of FPB2-WT revealed a putative Ets binding site possibly involved in the complex formation.
Indeed, we observed a clear competition using a 100-fold molar excess of a consensus Ets-1 oligonucleotide (Fig. 7B, lane 5) whereas an FPB2 oligonucleotide, mutated for the Ets binding site (FPB2m), failed to prevent the complex formation (Fig. 7B, lane 4) . Using antibodies directed against Erg 1/2 transcription factors or NERF 1/1b/2 factors we did not observe any supershift on DNA-protein complexes formed by HMEC-1 nuclear extracts and FPB2-WT probe (data not shown), suggesting that neither Erg nor NERF transcription factors were present in DNA-protein complexes.
The same study, performed with an FPD-WT probe, centered on the functional element D resulted in the formation of one major specific complex and several minor complexes ( Supershift experiments performed with FPD-WT probe using an antibody specifically directed against NERF 1/1b/2 factors did not allow supershifted bands to be observed (data not shown). In contrast, an antibody specifically targeted against Erg 1/2 transcription factors abolished formation of a minor complex formed with FPD-WT probe and nuclear extract (Fig. 
8A, lane 4).
Complementary data were obtained with HeLa cells transfected with several expression vectors encoding different Ets-related transcription factors. Only whole cell extracts of HeLa cells transfected with pSG5-p55-Erg and pCMV5-Elk-1 expression vectors led to specific DNA-protein complexes in EMSA experiments using FPB2-WT (Fig. 7B, lanes 2-3) or FPD-WT probes (Fig. 8B, lanes 3-4) . Cotransfection experiments in HMEC-1 showed a slight potentializing effect of Erg transcription factor on transcriptional activity of the enhancer compared to an empty vector (Fig. 9A ). Elk-1 over-expression led to a pronounced inhibition of transcriptional activity (Fig. 9C ) when co-expressed at a 1/1 ratio with pGL3-p2, but had no effect when used at a lower ratio (1/50) (data not shown). Similar experiments using Ergexpression vector and pGL3-p2 in HeLa cells showed a significant effect of Erg on unidentified Ets binding sites located in the first 1703 bp of the promoter sequence (Fig. 9B,   lanes 1-2) . It is therefore difficult to assess the effect of p55Erg on the enhancer (Fig. 9B) .
However the effect of Erg, as tested by a test of interaction, was significant both in HMEC-1 and 
Endothelial specificity of the transcription factors interactions
To test the hypothesis of an endothelial specificity of transcription factors implicated in the enhancer function, we performed EMSA experiments using HeLa nuclear extracts and the different EMSA probes and we compared the migration patterns with those obtained using HMEC-1 nuclear extracts. No difference could be observed using the two nuclear extracts and the FPA-WT, FPB2-WT and FPC 1-3 -WT probes (data not shown). However, the Erg-related complex observed using FPD-WT probe was not present when using HeLa cell nuclear extracts, even at longer exposure (Fig. 11) .
Discussion
In order to identify new cis-regulatory elements of the heNOS gene, we surveyed 16. 
Indeed, we identified a MZF-1 consensus binding sequence in footprint A and in region C2
(footprint C), whose binding specificity were confirmed by competition in EMSA experiments using an oligonucleotide containing an unrelated MZF-1 binding site (26) . It is also striking that the two linker-scanning mutants disrupting each MZF-half-site in the 269 bp enhancer (mutants LSA and LSC2) show a similar decrease in transcriptional activity, suggesting that the full activation requires an intact 2 half-sites structures. The long distance between these half-sites (50 bp) is consistent with a recent model for another two zinc-finger-domains transcription factor whose binding sites are separated by 44 bp (27) and also with the identification, in the Factor XIII promoter, of two active MZF-1 half sites almost 140 bp apart (25) . However, using antibodies directed against these MZF isoforms, we did not observe any supershift or modification of the complexes formed with probe A. In addition, cotransfections of an MZF-1 expression vector did not show a transactivating effect of MZF-1 on the enhancer activity (data not shown). Therefore, although our data support the implication of an MZF-like factor, based on consensus sequence homology and competition experiments, they do not favor a direct role for MZF-1 or MZF-2 in the enhancer activity. However, we can hypothesize that an MZFrelated factor is at play, as an example, MZF-3, an MZF-related transcription factor, which was recently described in the mouse (Genebank access# AF082568). Its potential implication remains to be evaluated when more information is available.
Region C2 is likely to bind Sp-1-related factor, since complexes are competed away with an Sp-1 consensus oligonucleotide. Sp-1 binding site is also a major regulatory element of the proximal heNOS promoter for constitutive (9) (10) (11) (12) cotransfection experiments, Elk-1 strongly inhibits the enhancer activity when large amounts of vector were cotransfected whereas Ets-1, Ets-2 or Elf-1 did not show any effect at any cotransfection ratio. The Elk-1-induced inhibition seems to be due to the expression of high amounts of Elk-1 (as observed in EMSA experiments), which suggests that it is the consequence of a strong competition of Elk-1 for native HMEC-1 Ets-related factors which bind B2 or D sites. Among the other Ets-related factors tested, Ets-1 and Ets-2 transactivated only the proximal promoter of heNOS (data not shown), as was shown in previous studies (12) .
Taken together, these results support the hypothesis that Erg-like factors could participate in the heNOS enhancer activity, although other still unidentified Ets factors are likely to be also involved. Supershift experiments using element D probe, showed that a single faint complex was displaced by an anti-Erg antibody, whereas several other complexes were not affected. These complexes likely involve Ets-like factors because they are competed away by an oligonucleotide bearing the Ets consensus sequence. However, none of these could be detected in the complexes by using an antibody against several Ets factors. In contrast, an Ets factor does not seem to be implicated in region C3, although it contains an Ets core consensus sequence.
When results obtained using constructs where mutations are restricted to the core Ets site are compared to results obtained using corresponding linker-scanning mutants which involve flanking nucleotides (pGL3-p2-LSB2 and pGL3-p2-LSD), the transcriptional effect of the latter appears more pronounced. It is therefore likely that linker-scanning mutations affect the binding ability of proteins adjacent to the core Ets site.
Interestingly, using a 5.2 kb fragment of the mouse eNOS promoter driving the β- In conclusion, an enhancer was identified at distance from the transcription start site.
Complex interactions between several elements located in the activator region can be inferred from our results. Among all transcription factors tested, Erg was the single transcription factor able to bind the enhancer and transactivate the promoter. Other important transcription factors involved in the transactivating activity and probably belonging to the MZF and Ets family remain to be identified. Linker-scanning mutations were introduced in pGL3-p2 construct by substituting 8 to 10 bp in the different regions protected by DNase I footprinting (see Table I ). Boxes represent DNase I protected elements A, B, C and D. Black crosses represent linker-scanning mutations. Sequence of mutations are described in Table I . Transcriptional activities of enhancer construct pGL3-p2
and of the different linker-scanning mutants were compared with that of pGL3-1703 promoter. identify specific nucleo-protein complexes, using different oligonucleotides, from a 10-fold (lanes 3, 5, 7, 9, 13, 15, 17 ) to a 100-fold (lanes 4, 6, 8, 10, 14, 16, 18 ) molar excess.
Oligonucleotides used are defined in Table II. Specific DNA-protein complexes (I, II, III, IV) are indicated by arrows. and then submitted to electrophoresis in 7% acrylamide, 0.5X TBE native gel. Different competition studies (lanes 3-6 and 9-10) were performed using a 100-fold molar excess of indicated cold oligonucleotides (oligonucleotides sequences are in Table II) . Arrows indicate specific nucleo-protein complexes which are named I to V. Transcriptional activity of the Ets core binding site mutations (pGL3-p2-Ets4775 mut, pGL3-p2-Ets4688 mut) and of the corresponding linker-scanning mutants (respectively pGL3-p2-LSB2
and pGL3-p2-LSD) were measured and compared to the 1703 bp promoter activity. Full enhancer activity was also measured (pGL3-p2). Data represent the mean ± S.E.M. of four experiments, * p<0.05, relative to pGL3-p2.
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